Lipid metabolism in myelinating glial cells: Lessons from human inherited disorders and mouse models

Journal of Lipid Research

Volumn 52, Issue 3, 2011, Pages 419-434

  Chrast, Roman ^a   Saher, Gesine ^b   Nave, Klaus Armin ^b   Verheijen, Mark H G ^c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLYCOLIPID; MYELIN; MYELIN PROTEIN;

BLOOD BRAIN BARRIER; DISEASE MODEL; DISEASE PREDISPOSITION; GLIA CELL; HUMAN; INHERITANCE; LIPID COMPOSITION; LIPID METABOLISM; LIPID TRANSPORT; LIPOGENESIS; METABOLIC DISORDER; MOUSE; MYELIN SHEATH; MYELINATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LIPID METABOLISM; METABOLIC DISEASES; MICE; MYELIN SHEATH; NEUROGLIA;

EID: 79953188349     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R009761     Document Type: Review

References (175)

1. Barres, B. A. 2008. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron. 60:430-440.
2. Franz, D. N., and A. Iggo. 1968. Conduction failure in myelinated and non-myelinated axons at low temperatures. J. Physiol. 199 : 319-345.
3. Waxman, S. G. 1980. Determinants of conduction velocity in myelinated nerve fibers. Muscle Nerve. 3:141-150. (Pubitemid 10134621)
4. Hartline, D. K., and D. R. Colman. 2007. Rapid conduction and the evolution of giant axons and myelinated fibers. Curr. Biol. 17:R29-R35.
5. Norton, W. T., and S. E. Poduslo. 1973. Myelination in rat brain: method of myelin isolation. J. Neurochem. 21:749-757.
6. Norton, W. T., and S. E. Poduslo. 1973. Myelination in rat brain: changes in myelin composition during brain maturation. J. Neurochem. 21:759-773.
7. Garbay, B., A. M. Heape, F. Sargueil, and C. Cassagne. 2000. Myelin synthesis in the peripheral nervous system. Prog. Neurobiol. 61:267-304.
8. Saher, G., and M. Simons. 2010. Cholesterol and myelin biogenesis. Subcell. Biochem. 51:489-508.
9. Norton, W. T., and W. Cammer. 1984. Isolation and characterization of myelin. In Myelin. P. Morell, editor. Plenum, New York. 147-180.
10. Stoffel, W., and A. Bosio. 1997. Myelin glycolipids and their functions. Curr. Opin. Neurobiol. 7:654-661.
11. Eckhardt, M. 2008. The role and metabolism of sulfatide in the nervous system. Mol. Neurobiol. 37:93-103.
12. Nagan, N., and R. A. Zoeller. 2001. Plasmalogens: biosynthesis and functions. Prog. Lipid Res. 40:199-229.
13. Balakrishnan, S., H. Goodwin, and J. N. Cumings. 1961. The distribution of phosphorus-containing lipid compounds in the human brain. J. Neurochem. 8:276-284.
14. Morell, P., and R.H. Quarles. 1999. Myelin formation, structure and biochemistry. In Basic Neurochemistry. J. S. George, B. W. Agranoff, R. W. Albers, S. F. Fisher, and M. D. Uhler, editors. Lippincott-Raven, Philedelphia.
15. Sowell, E. R., B. S. Peterson, P. M. Thompson, S. E. Welcome, A. L. Henkenius, and A. W. Toga. 2003. Mapping cortical change across the human life span. Nat. Neurosci. 6:309-315.
16. Yakovlev, P. I., and A. R. Lecours. 1967. The myelogenetic cycles of regional maturation of the brain. In Regional Development of the Brain in Early Life. A. Minkowski, editor. Blackwell Scientific, Oxford. 3-70.
17. Muse, E. D., H. Jurevics, A. D. Toews, G. K. Matsushima, and P. Morell. 2001. Parameters related to lipid metabolism as markers of myelination in mouse brain. J. Neurochem. 76:77-86. (Pubitemid 32044370)
18. Baron, W., and D. Hoekstra. 2009. On the biogenesis of myelin membranes: sorting, trafficking and cell polarity. FEBS Lett. 584 : 1760-1770.
19. Webster, H. D. 1971. The geometry of peripheral myelin sheaths during their formation and growth in rat sciatic nerves. J. Cell Biol. 48:348-367.
20. Heape, A., H. Juguelin, M. Fabre, F. Boiron, B. Garbay, M. Fournier, J. Bonnet, and C. Cassagne. 1986. Correlation between the morphology and the lipid and protein compositions in the peripheral nervous system of individual 8-day-old normal and trembler mice. Brain Res. 390:173-180. (Pubitemid 16188170)
21. Heape, A., H. Juguelin, M. Fabre, F. Boiron, and C. Cassagne. 1986. A quantitative developmental study of the peripheral nerve lipid composition during myelinogenesis in normal and trembler mice. Brain Res. 390:181-189. (Pubitemid 16188171)
22. Heape, A., F. Boiron, and C. Cassagne. 1987. A developmental study of fatty acyl group contents in the peripheral nervous system of normal and trembler mice. Neurochem. Pathol. 7:157-167.
23. Nagarajan, R., N. Le, H. Mahoney, T. Araki, and J. Milbrandt. 2002. Deciphering peripheral nerve myelination by using Schwann cell expression profiling. Proc. Natl. Acad. Sci. USA. 99:8998-9003.
24. Verheijen, M. H., R. Chrast, P. Burrola, and G. Lemke. 2003. Local regulation of fat metabolism in peripheral nerves. Genes Dev. 17:2450-2464. (Pubitemid 37214792)
25. Ando, S., Y. Tanaka, Y. Toyoda, and K. Kon. 2003. Turnover of myelin lipids in aging brain. Neurochem. Res. 28:5-13.
26. Dyck, P. J., and P. K. Thomas. 2005. Lysosomal and peroxisomal disorders. In Peripheral Neuropathy. Elsevier Saunders, Philadelphia, PA. 1845-1882.
27. Wanders, R. J., S. Ferdinandusse, P. Brites, and S. Kemp. 2010. Peroxisomes, lipid metabolism and lipotoxicity. Biochim. Biophys. Acta. 1801:272-280.
28. Horster, F., R. Surtees, and G. F. Hoffmann. 2005. Disorders of intermediary metabolism: toxic leukoencephalopathies. J. Inherit. Metab. Dis. 28:345-356.
29. Verrips, A., L. H. Hoefsloot, G. C. Steenbergen, J. P. Theelen, R. A. Wevers, F. J. Gabreels, B. G. van Engelen, and L. P. van den Heuvel. 2000. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain. 123:908-919. (Pubitemid 30224187)
30. Gallus, G. N., M. T. Dotti, and A. Federico. 2006. Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol. Sci. 27:143-149.
31. Pietrini, V., N. Rizzuto, C. Vergani, F. Zen, and F. Ferro Milone. 1985. Neuropathy in Tangier disease: A clinicopathologic study and a review of the literature. Acta Neurol. Scand. 72:495-505.
32. Pollock, M., H. Nukada, R. W. Frith, J. P. Simcock, and S. Allpress. 1983. Peripheral neuropathy in Tangier disease. Brain. 106:911-928. (Pubitemid 14245090)
33. Neklason, D. W., K. M. Andrews, R. I. Kelley, and J. E. Metherall. 1999. Biochemical variants of Smith-Lemli-Opitz syndrome. Am. J. Med. Genet. 85:517-523.
34. Witsch-Baumgartner, M., B. U. Fitzky, M. Ogorelkova, H. G. Kraft, F. F. Moebius, H. Glossmann, U. Seedorf, G. Gillessen-Kaesbach, G. F. Hoffmann, P. Clayton, et al. 2000. Mutational spectrum in the Delta7-sterol reductase gene and genotype-phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome. Am. J. Hum. Genet. 66:402-412.
35. Ciara, E., M. J. Nowaczyk, M. Witsch-Baumgartner, E. Malunowicz, E. Popowska, A. Jezela-Stanek, M. Piotrowicz, J. S. Waye, G. Utermann, and M. Krajewska-Walasek. 2004. DHCR7 mutations and genotype-phenotype correlation in 37 Polish patients with Smith-Lemli-Opitz syndrome. Clin. Genet. 66:517-524.
36. Caruso, P. A., T. Y. Poussaint, A. A. Tzika, D. Zurakowski, L. G. Astrakas, E. R. Elias, C. Bay, and M. B. Irons. 2004. MRI and 1H MRS findings in Smith-Lemli-Opitz syndrome. Neuroradiology. 46:3-14.
37. Kelley, R. I., and R. C. Hennekam. 2000. The Smith-Lemli-Opitz syndrome. J. Med. Genet. 37:321-335.
38. Curry, C. J., J. C. Carey, J. S. Holland, D. Chopra, R. Fineman, M. Golabi, S. Sherman, R. A. Pagon, J. Allanson, S. Shulman, et al. 1987. Smith-Lemli-Opitz syndrome-type II: multiple congenital anomalies with male pseudohermaphroditism and frequent early lethality. Am. J. Med. Genet. 26:45-57.
39. Ryan, A. K., K. Bartlett, P. Clayton, S. Eaton, L. Mills, D. Donnai, R. M. Winter, and J. Burn. 1998. Smith-Lemli-Opitz syndrome: a variable clinical and biochemical phenotype. J. Med. Genet. 35:558-565.
40. Berry, R., H. Wilson, J. Robinson, C. Sandlin, W. Tyson, J. Campbell, R. Porreco, and D. Manchester. 1989. Apparent Smith-Lemli-Opitz syndrome and Miller-Dieker syndrome in a family with segregating translocation t(7;17)(q34;p13.1). Am. J. Med. Genet. 34:358-365.
41. Cherstvoy, E. D., G. I. Lazjuk, T. I. Ostrovskaya, I. A. Shved, G. I. Kravtzova, I. W. Lurie, and A. I. Gerasimovich. 1984. The Smith-Lemli-Opitz syndrome. A detailed pathological study as a clue to a etiological heterogeneity. Virchows Arch. 404:413-425.
42. Ness, G. C., D. Lopez, O. Borrego, and E. Gilbert-Barness. 1997. Increased expression of low-density lipoprotein receptors in a Smith-Lemli-Opitz infant with elevated bilirubin levels. Am. J. Med. Genet. 68:294-299.
43. Fierro, M., A. J. Martinez, J. W. Harbison, and S. H. Hay. 1977. Smith-Lemli-Opitz syndrome: neuropathological and ophthalmological observations. Dev. Med. Child Neurol. 19:57-62.
44. Elias, E. R., M. B. Irons, A. D. Hurley, G. S. Tint, and G. Salen. 1997. Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS). Am. J. Med. Genet. 68:305-310.
45. Irons, M., E. R. Elias, D. Abuelo, M. J. Bull, C. L. Greene, V. P. Johnson, L. Keppen, C. Schanen, G. S. Tint, and G. Salen. 1997. Treatment of Smith-Lemli-Opitz syndrome: results of a multicenter trial. Am. J. Med. Genet. 68:311-314.
46. Porter, F. D. 2000. RSH/Smith-Lemli-Opitz syndrome: a multiple congenital anomaly/mental retardation syndrome due to an inborn error of cholesterol biosynthesis. Mol. Genet. Metab. 71:163-174.
47. Starck, L., I. Bjorkhem, E. M. Ritzen, B. Y. Nilsson, and U. von Dobeln. 1999. Beneficial effects of dietary supplementation in a disorder with defective synthesis of cholesterol. A case report of a girl with Smith-Lemli-Opitz syndrome, polyneuropathy and precocious puberty. Acta Paediatr. 88:729-733.
48. Fitzky, B. U., F. F. Moebius, H. Asaoka, H. Waage-Baudet, L. Xu, G. Xu, N. Maeda, K. Kluckman, S. Hiller, H. Yu, et al. 2001. 7-Dehydrocholesterol- dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome. J. Clin. Invest. 108:905-915.
49. Wassif, C. A., P. Zhu, L. Kratz, P. A. Krakowiak, K. P. Battaile, F. F. Weight, A. Grinberg, R. D. Steiner, N. A. Nwokoro, R. I. Kelley, et al. 2001. Biochemical, phenotypic and neurophysiological characterization of a genetic mouse model of RSH/Smith-Lemli-Opitz syndrome. Hum. Mol. Genet. 10:555-564.
50. Correa-Cerro, L. S., C. A. Wassif, L. Kratz, G. F. Miller, J. P. Munasinghe, A. Grinberg, S. J. Fliesler, and F. D. Porter. 2006. Development and characterization of a hypomorphic Smith-Lemli-Opitz syndrome mouse model and efficacy of simvastatin therapy. Hum. Mol. Genet. 15:839-851.
51. Saher, G., B. Brugger, C. Lappe-Siefke, W. Mobius, R. Tozawa, M. C. Wehr, F. Wieland, S. Ishibashi, and K. A. Nave. 2005. High cholesterol level is essential for myelin membrane growth. Nat. Neurosci. 8:468-475.
52. Saher, G., S. Quintes, W. Mobius, M. C. Wehr, E. M. Kramer-Albers, B. Brugger, and K. A. Nave. 2009. Cholesterol regulates the endoplasmic reticulum exit of the major membrane protein P0 required for peripheral myelin compaction. J. Neurosci. 29:6094-6104.
53. von Figura, K., V. Gieselmann, and J. Jaeken. 2001. Metachromatic leukodystrophy. In The Metabolic And Molecular Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, D. Valle, W. S. Sly, editors. McGraw Hill, New York. 3695-3724.
54. Landrieu, P., and G. Said. 1984. Peripheral neuropathy in type A Niemann-Pick disease. A morphological study. Acta Neuropathol. 63:66-71.
55. Suzuki, K. 2003. Globoid cell leukodystrophy (Krabbe's disease): update. J. Child Neurol. 18:595-603. (Pubitemid 37258464)
56. Schuchman, E. H., and R. J. Desnick. 2001. Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies. In The Metabolic and Molecular Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, D. Valle, B. Childs, K. W. Kinzler, and B. Vogelstein, editors. McGraw-Hill, New York. 3589-3610.
57. Edvardson, S., H. Hama, A. Shaag, J. M. Gomori, I. Berger, D. Soffer, S. H. Korman, I. Taustein, A. Saada, and O. Elpeleg. 2008. Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am. J. Hum. Genet. 83:643-648.
58. Dick, K. J., M. Eckhardt, C. Paisan-Ruiz, A. A. Alshehhi, C. Proukakis, N. A. Sibtain, H. Maier, R. Sharifi, M. A. Patton, W. Bashir, et al. 2010. Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum. Mutat. 31:E1251-E1260.
59. Alderson, N. L., B. M. Rembiesa, M. D. Walla, A. Bielawska, J. Bielawski, and H. Hama. 2004. The human FA2H gene encodes a fatty acid 2-hydroxylase. J. Biol. Chem. 279:48562-48568.
60. Zoller, I., M. Meixner, D. Hartmann, H. Bussow, R. Meyer, V. Gieselmann, and M. Eckhardt. 2008. Absence of 2-hydroxylated sphingolipids is compatible with normal neural development but causes late-onset axon and myelin sheath degeneration. J. Neurosci. 28:9741-9754.
61. Enquist, I. B., C. Lo Bianco, A. Ooka, E. Nilsson, J. E. Mansson, M. Ehinger, J. Richter, R. O. Brady, D. Kirik, and S. Karlsson. 2007. Murine models of acute neuronopathic Gaucher disease. Proc. Natl. Acad. Sci. USA. 104:17483-17488.
62. Hailemariam, T. K., C. Huan, J. Liu, Z. Li, C. Roman, M. Kalbfeisch, H. H. Bui, D. A. Peake, M. S. Kuo, G. Cao, et al. 2008. Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation. Arterioscler. Thromb. Vasc. Biol. 28:1519-1526.
63. Marcus, J., S. Honigbaum, S. Shroff, K. Honke, J. Rosenbluth, and J. L. Dupree. 2006. Sulfatide is essential for the maintenance of CNS myelin and axon structure. Glia. 53:372-381.
64. Hoshi, T., A. Suzuki, S. Hayashi, K. Tohyama, A. Hayashi, Y. Yamaguchi, K. Takeuchi, and H. Baba. 2007. Nodal protrusions, increased Schmidt-Lanterman incisures, and paranodal disorganization are characteristic features of sulfatide-deficient peripheral nerves. Glia. 55:584-594. (Pubitemid 46474300)
65. Coetzee, T., N. Fujita, J. Dupree, R. Shi, A. Blight, K. Suzuki, and B. Popko. 1996. Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell. 86:209-219. (Pubitemid 26286104)
66. Saadat, L., J. L. Dupree, J. Kilkus, X. Han, M. Traka, R. L. Proia, G. Dawson, and B. Popko. 2010. Absence of oligodendroglial glucosylceramide synthesis does not result in CNS myelin abnormalities or alter the dysmyelinating phenotype of CGT-deficient mice. Glia. 58:391-398.
67. Rizzo, W. B., G. Carney, and Z. Lin. 1999. The molecular basis of Sjogren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene. Am. J. Hum. Genet. 65:1547-1560.
68. Willemsen, M. A., M. Van Der Graaf, M. S. Van Der Knaap, A. Heerschap, P. H. Van Domburg, F. J. Gabreels, and J. J. Rotteveel. 2004. MR imaging and proton MR spectroscopic studies in Sjogren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am. J. Neuroradiol. 25:649-657.
69. van Domburg, P. H., M. A. Willemsen, J. J. Rotteveel, J. G. de Jong, H. O. Thijssen, A. Heerschap, J. R. Cruysberg, R. J. Wanders, F. J. Gabreels, and P. M. Steijlen. 1999. Sjogren-Larsson syndrome: clinical and MRI/MRS findings in FALDH-deficient patients. Neurology. 52:1345-1352.
70. Wierzbicki, A. S., M. D. Lloyd, C. J. Schofield, M. D. Feher, and F. B. Gibberd. 2002. Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. J. Neurochem. 80:727-735.
71. Steinberg, S. J., G. Dodt, G. V. Raymond, N. E. Braverman, A. B. Moser, and H. W. Moser. 2006. Peroxisome biogenesis disorders. Biochim. Biophys. Acta. 1763:1733-1748.
72. Mayatepek, E., M. Baumann, T. Meissner, F. Hanefeld, and G. C. Korenke. 2003. Role of leukotrienes as indicators of the inflammatory demyelinating reaction in x-linked cerebral adrenoleukodystrophy. J. Neurol. 250:1259-1260.
73. Kassmann, C. M., and K. A. Nave. 2008. Oligodendroglial impact on axonal function and survival-a hypothesis. Curr. Opin. Neurol. 21:235-241.
74. Van Veldhoven, P. P. 2010. Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism. J. Lipid Res. 51:2863-2895.
75. Imgrund, S., D. Hartmann, H. Farwanah, M. Eckhardt, R. Sandhoff, J. Degen, V. Gieselmann, K. Sandhoff, and K. Willecke. 2009. Adult ceramide synthase 2 (CERS2)-deficient mice exhibit myelin sheath defects, cerebellar degeneration, and hepatocarcinomas. J. Biol. Chem. 284:33549-33560.
76. Brites, P., P. A. Mooyer, L. El Mrabet, H. R. Waterham, and R. J. Wanders. 2009. Plasmalogens participate in very-long-chain fatty acid-induced pathology. Brain. 132:482-492.
77. Brites, P., A. M. Motley, P. Gressens, P. A. Mooyer, I. Ploegaert, V. Everts, P. Evrard, P. Carmeliet, M. Dewerchin, L. Schoonjans, et al. 2003. Impaired neuronal migration and endochondral ossifi cation in Pex7 knockout mice: a model for rhizomelic chondrodysplasia punctata. Hum. Mol. Genet. 12:2255-2267.
78. Maxwell, M., J. Bjorkman, T. Nguyen, P. Sharp, J. Finnie, C. Paterson, I. Tonks, B. C. Paton, G. F. Kay, and D. I. Crane. 2003. Pex13 inactivation in the mouse disrupts peroxisome biogenesis and leads to a Zellweger syndrome phenotype. Mol. Cell. Biol. 23:5947-5957.
79. Faust, P. L., and M. E. Hatten. 1997. Targeted deletion of the PEX2 peroxisome assembly gene in mice provides a model for Zellweger syndrome, a human neuronal migration disorder. J. Cell Biol. 139:1293-1305.
80. Baes, M., and P. Aubourg. 2009. Peroxisomes, myelination, and axonal integrity in the CNS. Neuroscientist. 15:367-379.
81. Baes, M., P. Gressens, E. Baumgart, P. Carmeliet, M. Casteels, M. Fransen, P. Evrard, D. Fahimi, P. E. Declercq, D. Collen, et al. 1997. A mouse model for Zellweger syndrome. Nat. Genet. 17:49-57.
82. Kassmann, C. M., C. Lappe-Siefke, M. Baes, B. Brugger, A. Mildner, H. B. Werner, O. Natt, T. Michaelis, M. Prinz, J. Frahm, et al. 2007. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat. Genet. 39:969-976.
83. Powers, J. M., Y. Liu, A. B. Moser, and H. W. Moser. 1992. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J. Neuropathol. Exp. Neurol. 51:630-643.
84. Ito, M., B. M. Blumberg, D. J. Mock, A. D. Goodman, A. B. Moser, H. W. Moser, K. D. Smith, and J. M. Powers. 2001. Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J. Neuropathol. Exp. Neurol. 60:1004-1019.
85. elMasry, M. N., and R. R. Rich. 1989. Prostaglandin E2 selectively increases interferon gamma receptor expression on human CD8+ lymphocytes. J. Clin. Invest. 83:1436-1440.
86. Jozefowski, S., R. Biedron, M. Bobek, and J. Marcinkiewicz. 2005. Leukotrienes modulate cytokine release from dendritic cells. Immunology. 116:418-428. (Pubitemid 41713173)
87. Schepers, L., M. Casteels, J. Vamecq, G. Parmentier, P. P. Van Veldhoven, and G. P. Mannaerts. 1988. Beta-oxidation of the carboxyl side chain of prostaglandin E2 in rat liver peroxisomes and mitochondria. J. Biol. Chem. 263:2724-2731.
88. Ferdinandusse, S., T. Meissner, R. J. Wanders, and E. Mayatepek. 2002. Identification of the peroxisomal beta-oxidation enzymes involved in the degradation of leukotrienes. Biochem. Biophys. Res. Commun. 293:269-273.
89. Rodemer, C., T. P. Thai, B. Brugger, T. Kaercher, H. Werner, K. A. Nave, F. Wieland, K. Gorgas, and W. W. Just. 2003. Inactivation of ether lipid biosynthesis causes male infertility, defects in eye development and optic nerve hypoplasia in mice. Hum. Mol. Genet. 12:1881-1895.
90. Teigler, A., D. Komljenovic, A. Draguhn, K. Gorgas, and W. W. Just. 2009. Defects in myelination, paranode organization and Purkinje cell innervation in the ether lipid-deficient mouse cerebellum. Hum. Mol. Genet. 18:1897-1908.
91. Tamby, J. P., P. Reinaud, and G. Charpigny. 1996. Preferential esterifi cation of arachidonic acid into ethanolamine phospholipids in epithelial cells from ovine endometrium. J. Reprod. Fertil. 107:23-30.
92. Brites, P., H. R. Waterham, and R. J. Wanders. 2004. Functions and biosynthesis of plasmalogens in health and disease. Biochim. Biophys. Acta. 1636:219-231.
93. Marin-Valencia, I., C. R. Roe, and J. M. Pascual. 2010. Pyruvate carboxylase deficiency: mechanisms, mimics and anaplerosis. Mol. Genet. Metab. 101:9-17.
94. Schiff, M., V. Levrat, C. Acquaviva, C. Vianey-Saban, M. O. Rolland, and N. Guffon. 2006. A case of pyruvate carboxylase deficiency with atypical clinical and neuroradiological presentation. Mol. Genet. Metab. 87:175-177.
95. Cesar, M., and B. Hamprecht. 1995. Immunocytochemical examination of neural rat and mouse primary cultures using monoclonal antibodies raised against pyruvate carboxylase. J. Neurochem. 64:2312-2318.
96. Shank, R. P., G. S. Bennett, S. O. Freytag, and G. L. Campbell. 1985. Pyruvate carboxylase: an astrocyte-specific enzyme implicated in the replenishment of amino acid neurotransmitter pools. Brain Res. 329:364-367.
97. Murin, R., M. Cesar, B. S. Kowtharapu, S. Verleysdonk, and B. Hamprecht. 2009. Expression of pyruvate carboxylase in cultured oligodendroglial, microglial and ependymal cells. Neurochem. Res. 34:480-489.
98. Namboodiri, A. M., A. Peethambaran, R. Mathew, P. A. Sambhu, J. Hershfield, J. R. Moffett, and C. N. Madhavarao. 2006. Canavan disease and the role of N-acetylaspartate in myelin synthesis. Mol. Cell. Endocrinol. 252:216-223.
99. Madhavarao, C. N., J. R. Moffett, R. A. Moore, R. E. Viola, M. A. Namboodiri, and D. M. Jacobowitz. 2004. Immunohistochemical localization of aspartoacylase in the rat central nervous system. J. Comp. Neurol. 472:318-329.
100. Adachi, M., L. Schneck, J. Cara, and B. W. Volk. 1973. Spongy degeneration of the central nervous system (van Bogaert and Bertrand type; Canavan's disease). A review. Hum. Pathol. 4:331-347.
101. Gascon, G. G., P. T. Ozand, A. Mahdi, A. Jamil, A. Haider, J. Brismar, and M. al-Nasser. 1990. Infantile CNS spongy degeneration-14 cases: clinical update. Neurology. 40:1876-1882.
102. Matalon, R. M., and K. Michals-Matalon. 2000. Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings. Front. Biosci. 5:D307-D311.
103. Traka, M., R. L. Wollmann, S. R. Cerda, J. Dugas, B. A. Barres, and B. Popko. 2008. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. J. Neurosci. 28:11537-11549.
104. Madhavarao, C. N., P. Arun, J. R. Moffett, S. Szucs, S. Surendran, R. Matalon, J. Garbern, D. Hristova, A. Johnson, W. Jiang, et al. 2005. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc. Natl. Acad. Sci. USA. 102:5221-5226.
105. Ledeen, R. W., J. Wang, G. Wu, Z. H. Lu, G. Chakraborty, M. Meyenhofer, S. K. Tyring, and R. Matalon. 2006. Physiological role of N-acetylaspartate: contribution to myelinogenesis. Adv. Exp. Med. Biol. 576:131-143; discussion 361-133.
106. Namboodiri, A. M., J. R. Moffett, P. Arun, R. Mathew, S. Namboodiri, A. Potti, J. Hershfield, B. Kirmani, D. M. Jacobowitz, and C. N. Madhavarao. 2006. Defective myelin lipid synthesis as a pathogenic mechanism of Canavan disease. Adv. Exp. Med. Biol. 576:145-163; discussion 361-143.
107. Chakraborty, G., P. Mekala, D. Yahya, G. Wu, and R. W. Ledeen. 2001. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J. Neurochem. 78:736-745.
108. Kumar, S., J. C. Biancotti, R. Matalon, and J. de Vellis. 2009. Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease. J. Neurosci. Res. 87:3415-3427.
109. Baslow, M. H., and D. N. Guilfoyle. 2009. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease? Neurochem. Res. 34:1523-1534.
110. Verheijen, M. H., N. Camargo, V. Verdier, K. Nadra, A. S. de Preux Charles, J. J. Medard, A. Luoma, M. Crowther, H. Inouye, H. Shimano, et al. 2009. SCAP is required for timely and proper myelin membrane synthesis. Proc. Natl. Acad. Sci. USA. 106:21383-21388.
111. Lee, A. G. 2003. Lipid-protein interactions in biological membranes: a structural perspective. Biochim. Biophys. Acta. 1612:1-40.
112. Simons, K., and W. L. Vaz. 2004. Model systems, lipid rafts, and cell membranes. Annu. Rev. Biophys. Biomol. Struct. 33:269-295.
113. Sankaram, M. B., and T. E. Thompson. 1990. Modulation of phospholipid acyl chain order by cholesterol. A solid-state 2H nuclear magnetic resonance study. Biochemistry. 29:10676-10684.
114. Huang, J., and G. W. Feigenson. 1999. A microscopic interaction model of maximum solubility of cholesterol in lipid bilayers. Biophys. J. 76:2142-2157.
115. Kakorin, S., U. Brinkmann, and E. Neumann. 2005. Cholesterol reduces membrane electroporation and electric deformation of small bilayer vesicles. Biophys. Chem. 117:155-171.
116. Pan, J., S. Tristram-Nagle, and J. F. Nagle. 2009. Effect of cholesterol on structural and mechanical properties of membranes depends on lipid chain saturation. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 80:021931.
117. Hofsass, C., E. Lindahl, and O. Edholm. 2003. Molecular dynamics simulations of phospholipid bilayers with cholesterol. Biophys. J. 84:2192-2206. (Pubitemid 36373542)
118. Wang, T. Y., and J. R. Silvius. 2003. Sphingolipid partitioning into ordered domains in cholesterol-free and cholesterol-containing lipid bilayers. Biophys. J. 84:367-378.
119. Kulkarni, K., D. S. Snyder, and T. J. McIntosh. 1999. Adhesion between cerebroside bilayers. Biochemistry. 38:15264-15271.
120. Ruocco, M. J., D. Atkinson, D. M. Small, R. P. Skarjune, E. Oldfield, and G. G. Shipley. 1981. X-ray diffraction and calorimetric study of anhydrous and hydrated N-palmitoylgalactosylsphingosine (cerebroside). Biochemistry. 20:5957-5966.
121. Bosio, A., E. Binczek, W. F. Haupt, and W. Stoffel. 1998. Composition and biophysical properties of myelin lipid define the neurological defects in galactocerebroside- and sulfatide-deficient mice. J. Neurochem. 70:308-315. (Pubitemid 28020857)
122. van Meer, G., D. R. Voelker, and G. W. Feigenson. 2008. Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol. 9:112-124.
123. Glaser, P. E., and R. W. Gross. 1994. Plasmenylethanolamine facilitates rapid membrane fusion: a stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane fusion. Biochemistry. 33:5805-5812.
124. Glaser, P. E., and R. W. Gross. 1995. Rapid plasmenylethano lamine-selective fusion of membrane bilayers catalyzed by an isoform of glyceraldehyde-3-phosphate dehydrogenase: discrimination between glycolytic and fusogenic roles of individual isoforms. Biochemistry. 34:12193-12203.
125. Sastry, P. S. 1985. Lipids of nervous tissue: composition and metabolism. Prog. Lipid Res. 24:69-176.
126. Hu, Y., I. Doudevski, D. Wood, M. Moscarello, C. Husted, C. Genain, J. A. Zasadzinski, and J. Israelachvili. 2004. Synergistic interactions of lipids and myelin basic protein. Proc. Natl. Acad. Sci. USA. 101:13466-13471.
127. Zhao, S., X. Hu, J. Park, Y. Zhu, Q. Zhu, H. Li, C. Luo, R. Han, N. Cooper, and M. Qiu. 2007. Selective expression of LDLR and VLDLR in myelinating oligodendrocytes. Dev. Dyn. 236:2708-2712.
128. Goodrum, J. F., K. A. Fowler, J. D. Hostettler, and A. D. Toews. 2000. Peripheral nerve regeneration and cholesterol reutilization are normal in the low-density lipoprotein receptor knockout mouse. J. Neurosci. Res. 59:581-586.
129. Simons, M., E. M. Kramer, C. Thiele, W. Stoffel, and J. Trotter. 2000. Assembly of myelin by association of proteolipid protein with cholesterol- and galactosylceramide-rich membrane domains. J. Cell Biol. 151:143-154.
130. Kramer-Albers, E. M., K. Gehrig-Burger, C. Thiele, J. Trotter, and K. A. Nave. 2006. Perturbed interactions of mutant proteolipid protein/DM20 with cholesterol and lipid rafts in oligodendroglia: implications for dysmyelination in spastic paraplegia. J. Neurosci. 26:11743-11752.
131. Bansal, R., S. Winkler, and S. Bheddah. 1999. Negative regulation of oligodendrocyte differentiation by galactosphingolipids. J. Neurosci. 19:7913-7924. (Pubitemid 30225789)
132. Hirahara, Y., R. Bansal, K. Honke, K. Ikenaka, and Y. Wada. 2004. Sulfatide is a negative regulator of oligodendrocyte differentiation: development in sulfatide-null mice. Glia. 45:269-277. (Pubitemid 38222255)
133. Nadra, K., A. S. de Preux Charles, J. J. Medard, W. T. Hendriks, G. S. Han, S. Gres, G. M. Carman, J. S. Saulnier-Blache, M. H. Verheijen, and R. Chrast. 2008. Phosphatidic acid mediates demyelination in Lpin1 mutant mice. Genes Dev. 22:1647-1661. (Pubitemid 351846844)
134. Huether, G., M. Klapproth, and V. Neuhoff. 1986. Fatty acid composition of myelin lipids from developing rat forebrain and spinal cord: influence of experimental hyperphenylalaninaemia. Neurochem. Res. 11:1303-1311.
135. Nave, K. A. 2010. Myelination and the trophic support of long axons. Natl. Rev. 11:275-283.
136. Chrast, R., M. H. Verheijen, and G. Lemke. 2004. Complement factors in adult peripheral nerve: a potential role in energy metabolism. Neurochem. Int. 45:353-359.
137. de Preux, A. S., K. Goosen, W. Zhang, A. A. Sima, H. Shimano, D. M. Ouwens, M. Diamant, J. L. Hillebrands, J. Rozing, G. Lemke, et al. 2007. SREBP-1c expression in Schwann cells is affected by diabetes and nutritional status. Mol. Cell. Neurosci. 35:525-534.
138. Verrips, A., R. A. Wevers, B. G. Van Engelen, A. Keyser, B. G. Wolthers, F. Barkhof, A. Stalenhoef, R. De Graaf, F. Janssen-Zijlstra, A. Van Spreeken, et al. 1999. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism. 48:233-238. (Pubitemid 29072281)
139. Saheki, A., T. Terasaki, I. Tamai, and A. Tsuji. 1994. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm. Res. 11:305-311.
140. Paintlia, A. S., M. K. Paintlia, M. Khan, T. Vollmer, A. K. Singh, and I. Singh. 2005. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. Faseb. J. 19:1407-1421. (Pubitemid 41278999)
141. Paintlia, A. S., M. K. Paintlia, A. K. Singh, and I. Singh. 2008. Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol. Pharmacol. 73:1381-1393.
142. Stanislaus, R., A. G. Gilg, A. K. Singh, and I. Singh. 2002. Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neurosci. Lett. 333:167-170.
143. Youssef, S., O. Stuve, J. C. Patarroyo, P. J. Ruiz, J. L. Radosevich, E. M. Hur, M. Bravo, D. J. Mitchell, R. A. Sobel, L. Steinman, and S. S. Zamvil. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 420:78-84.
144. Sena, A., R. Pedrosa, and M. Graca Morais. 2003. Therapeutic potential of lovastatin in multiple sclerosis. J. Neurol. 250:754-755. (Pubitemid 36718367)
145. Vollmer, T., L. Key, V. Durkalski, W. Tyor, J. Corboy, S. Markovic-Plese, J. Preiningerova, M. Rizzo, and I. Singh. 2004. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 363:1607-1608. (Pubitemid 38625664)
146. Maier, O., J. De Jonge, A. Nomden, D. Hoekstra, and W. Baron. 2009. Lovastatin induces the formation of abnormal myelin-like membrane sheets in primary oligodendrocytes. Glia. 57:402-413.
147. Gaist, D., U. Jeppesen, M. Andersen, L. A. Garcia Rodriguez, J. Hallas, and S. H. Sindrup. 2002. Statins and risk of polyneuropathy: a case-control study. Neurology. 58:1333-1337.
148. Law, M., and A. R. Rudnicka. 2006. Statin safety: a systematic review. Am. J. Cardiol. 97:52C-60C.
149. Brown, W. V. 2008. Safety of statins. Curr. Opin. Lipidol. 19:558-562.
150. Verhave, P. S., R. A. Vanwersch, H. P. van Helden, A. B. Smit, and I. H. Philippens. 2009. Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease. Behav. Brain Res. 200:214-219.
151. Jurevics, H. A., and P. Morell. 1994. Sources of cholesterol for kidney and nerve during development. J. Lipid Res. 35:112-120. (Pubitemid 24027997)
152. Morell, P., and H. Jurevics. 1996. Origin of cholesterol in myelin. Neurochem. Res. 21:463-470.
153. Kelley, R. I. 2000. Inborn errors of cholesterol biosynthesis. Adv. Pediatr. 47:1-53.
154. Ullrich, K., H. G. Koch, D. Meschede, U. Flotmann, and U. Seedorf. 1996. Smith-Lemli-Opitz syndrome: treatment with cholesterol and bile acids. Neuropediatrics. 27:111-112. (Pubitemid 26159380)
155. Arun, P., C. N. Madhavarao, J. R. Moffett, K. Hamilton, N. E. Grunberg, P. S. Ariyannur, W. A. Gahl, Y. Anikster, S. Mog, W. C. Hallows, et al. 2010. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease. J. Inherit. Metab. Dis. 33:195-210.
156. Das, A. K., R. D. Holmes, G. N. Wilson, and A. K. Hajra. 1992. Dietary ether lipid incorporation into tissue plasmalogens of humans and rodents. Lipids. 27:401-405.
157. Saito, K., V. Dubreuil, Y. Arai, M. Wilsch-Brauninger, D. Schwudke, G. Saher, T. Miyata, G. Breier, C. Thiele, A. Shevchenko, et al. 2009. Ablation of cholesterol biosynthesis in neural stem cells increases their VEGF expression and angiogenesis but causes neuron apoptosis. Proc. Natl. Acad. Sci. USA. 106:8350-8355.
158. Karasinska, J. M., F. Rinninger, D. Lutjohann, P. Ruddle, S. Franciosi, J. K. Kruit, R. R. Singaraja, V. Hirsch-Reinshagen, J. Fan, L. R. Brunham, et al. 2009. Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. J. Neurosci. 29:3579-3589.
159. Spencer, B. J., and I. M. Verma. 2007. Targeted delivery of proteins
160. Garbay, B., F. Boiron-Sargueil, M. Shy, T. Chbihi, H. Jiang, J. Kamholz, and C. Cassagne. 1998. Regulation of oleoyl-CoA synthesis in the peripheral nervous system: demonstration of a link with myelin synthesis. J. Neurochem. 71:1719-1726. (Pubitemid 28443046)
161. Yao, J. K., R. T. Holman, M. F. Lubozynski, and P. J. Dyck. 1980. Changes in fatty acid composition of peripheral nerve myelin in essential fatty acid deficiency. Arch. Biochem. Biophys. 204:175-180.
162. Bourre, J. M., A. Youyou, G. Durand, and G. Pascal. 1987. Slow recovery of the fatty acid composition of sciatic nerve in rats fed a diet initially low in n-3 fatty acids. Lipids. 22:535-538.
163. Retra, K., O. B. Bleijerveld, R. A. van Gestel, A. G. Tielens, J. J. van Hellemond, and J. F. Brouwers. 2008. A simple and universal method for the separation and identification of phospholipid molecular species. Rapid Commun. Mass Spectrom. 22:1853-1862.
164. Dod, B. J., and G. M. Gray. 1968. The lipid composition of rat-liver plasma membranes. Biochim. Biophys. Acta. 150:397-404.
165. Ray, T. K., V. P. Skipski, M. Barclay, E. Essner, and F. M. Archibald. 1969. Lipid composition of rat liver plasma membranes. J. Biol. Chem. 244:5528-5536.
166. Lorincz, M. T., S. Rainier, D. Thomas, and J. K. Fink. 2005. Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. Arch. Neurol. 62:1459-1463.
167. Brunham, L. R., R. R. Singaraja, and M. R. Hayden. 2006. Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. Annu. Rev. Nutr. 26:105-129.
168. Heim, P., M. Claussen, B. Hoffmann, E. Conzelmann, J. Gartner, K. Harzer, D. H. Hunneman, W. Kohler, G. Kurlemann, and A. Kohlschutter. 1997. Leukodystrophy incidence in Germany. Am. J. Med. Genet. 71:475-478.
169. Gustavson, K. H., and B. Hagberg. 1971. The incidence and genetics of metachromatic leucodystrophy in northern Sweden. Acta Paediatr. Scand. 60:585-590.
170. Schuchman, E. H. 2007. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J. Inherit. Metab. Dis. 30:654-663.
171. Jagell, S., K. H. Gustavson, and G. Holmgren. 1981. Sjogren-Larsson syndrome in Sweden. A clinical, genetic and epidemiological study. Clin. Genet. 19:233-256.
172. Lazarow, P. B., and H. W. Moser. 1989. Disorders of peroxisome biogenesis. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 1479-1509.
173. Berger, J., and J. Gartner. 2006. X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects. Biochim. Biophys. Acta. 1763:1721-1732.
174. Feigenbaum, A., R. Moore, J. Clarke, S. Hewson, D. Chitayat, P. N. Ray, and T. L. Stockley. 2004. Canavan disease: carrier-frequency determination in the Ashkenazi Jewish population and development of a novel molecular diagnostic assay. Am. J. Med. Genet. A. 124A:142-147.
175. Brun, N., Y. Robitaille, A. Grignon, B. H. Robinson, G. A. Mitchell, and M. Lambert. 1999. Pyruvate carboxylase deficiency: prenatal onset of ischemia-like brain lesions in two sibs with the acute neonatal form. Am. J. Med. Genet. 84:94-101.